Switch theme
Sign up to access all valuation multiples
Spineway designs produce and markets implant lines and ancillary surgical equipment used for the treatment of severe disorders of the spinal column. The group offers spinal systems, cervical and lumbar cages, cervical plates, bone substitutes, and other such medical instruments.
2005
54
LTM Revenue $13.8M
LTM EBITDA -$1.3M
$2.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spineway has a last 12-month revenue of $13.8M and a last 12-month EBITDA of -$1.3M.
In the most recent fiscal year, Spineway achieved revenue of $11.3M and an EBITDA of -$3.9M.
Spineway expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spineway valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.0M | $11.3M | XXX | XXX | XXX |
| Gross Profit | $3.8M | $6.4M | XXX | XXX | XXX |
| Gross Margin | 48% | 57% | XXX | XXX | XXX |
| EBITDA | -$2.2M | -$3.9M | XXX | XXX | XXX |
| EBITDA Margin | -28% | -35% | XXX | XXX | XXX |
| Net Profit | -$1.6M | -$3.4M | XXX | XXX | XXX |
| Net Margin | -20% | -30% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Spineway's stock price is EUR 0 (or $0).
Spineway has current market cap of EUR 2.4M (or $2.5M), and EV of EUR 2.6M (or $2.8M).
See Spineway trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8M | $2.5M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Spineway has market cap of $2.5M and EV of $2.8M.
Spineway's trades at 0.2x LTM EV/Revenue multiple, and -2.1x LTM EBITDA.
Analysts estimate Spineway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Spineway and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSpineway's NTM/LTM revenue growth is 19%
Spineway's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Spineway's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Spineway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Spineway and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 78% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -15% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 118% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spineway acquired XXX companies to date.
Last acquisition by Spineway was XXXXXXXX, XXXXX XXXXX XXXXXX . Spineway acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Spineway founded? | Spineway was founded in 2005. |
| Where is Spineway headquartered? | Spineway is headquartered in France. |
| How many employees does Spineway have? | As of today, Spineway has 54 employees. |
| Is Spineway publicy listed? | Yes, Spineway is a public company listed on PAR. |
| What is the stock symbol of Spineway? | Spineway trades under ALSPW ticker. |
| When did Spineway go public? | Spineway went public in 2013. |
| Who are competitors of Spineway? | Similar companies to Spineway include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Spineway? | Spineway's current market cap is $2.5M |
| What is the current revenue of Spineway? | Spineway's last 12-month revenue is $13.8M. |
| What is the current EBITDA of Spineway? | Spineway's last 12-month EBITDA is -$1.3M. |
| What is the current EV/Revenue multiple of Spineway? | Current revenue multiple of Spineway is 0.2x. |
| What is the current EV/EBITDA multiple of Spineway? | Current EBITDA multiple of Spineway is -2.1x. |
| What is the current revenue growth of Spineway? | Spineway revenue growth between 2023 and 2024 was 42%. |
| Is Spineway profitable? | Yes, Spineway is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
